Block & Leviton LLP a national securities litigation firm, reminds investors that securities class actions have been filed against GoHealth, Inc. NextCure, Inc. and Aurora Cannabis Inc. . Shareholders interested in serving as lead plaintiff have until the deadlines listed below to move the court. Further details about the cases are described below. There is no cost or obligation to you. GOCO Shareholders – Click ...

Block & Leviton LLP ( www.blockleviton.com ), a national securities litigation firm, reminds investors that securities class actions have been filed against GoHealth, Inc. (NASDAQ: GOCO), NextCure, Inc. (NASDAQ: NXTC), and Aurora Cannabis Inc. (NYSE: ACB). Shareholders interested in serving as lead plaintiff have until the deadlines listed below to move the court. Further details about the cases are described below. There is no cost or obligation to you.

GOCO Shareholders – Click Here: https://www.blockleviton.com/cases/goco

NXTC Shareholders – Click Here: https://www.blockleviton.com/cases/nxtc

ACB Shareholders – Click Here: https://www.blockleviton.com/cases/acb

GoHealth, Inc. (NASDAQ: GOCO) – Lead Plaintiff Deadline of November 20, 2020

In July 2020, GoHealth went public, selling stock to investors at $21 per share. Just one month later, GoHealth reported an almost $23 million quarterly loss, in sharp contrast to the $15 million profit it earned in the prior year period. A lawsuit has been filed against GoHealth in the U.S. District Court for the Northern District of Illinois. The suit alleges that GoHealth's executives admitted that customer churn matched internal Company "expectations" and that churn was increasing, as internally expected, before and at the time of the IPO. However, GoHealth never revealed this information to its investors. On this news, GoHealth's stock fell from its August 19, 2020 closing price of $19.02 per share to an August 21, 2020 close of $15.97 per share. GoHealth's stock has since closed as low as $12.53 per share, representing a decline of over 40% from the IPO price.

NextCure , Inc. (NASDAQ: NXTC ) – Lead Plaintiff Deadline of November 20 , 2020

On July 13, 2020, NextCure shocked the markets when it announced that it no longer planned to advance the monotherapy trial for its lead product candidate, NC318, in non-small cell lung cancer and ovarian cancer. On the same day, NextCure announced the resignation of its Chief Medical Officer, Kevin N. Heller, M.D. On this news, the price of NextCure common stock plummeted over 54% in one day, closing at just $8.15 per share.

A lawsuit has been filed in the U.S. District Court for the Southern District of New York against NextCure and certain of its officers and directors. The suit, which has a class period running from November 5, 2019 to July 14, 2020, alleges that beginning in November 2019, NextCure issued a series of misstatements that misled investors with respect to the efficacy of and objective responses observed in patients treated with NC318 in the Company's Phase 1 clinical trial for non-small cell lung cancer and ovarian cancer. The lawsuit further alleges that NextCure used these misstatements to artificially prop up the price of its stock to support a November 19, 2019 public offering of $150 million of the Company's common stock, at $36.75 per share. According to the lawsuit, the July 13, 2020 news that NextCure was no longer advancing the NC318 trial was so shocking because of the Company's previous statements touting the positive results of NextCure's Phase 1 trial for NC318.

Aurora Cannabis Inc. ( NYSE: ACB ) – Lead Plaintiff Deadline of December 1 , 2020

On September 8, 2020, Aurora Cannabis Inc. stunned the market when it announced that it expected to record up to $1.8 billion in goodwill impairment charges in the fourth quarter of 2020. On the same day, Aurora also announced a charge of approximately $140 million in the carrying value of certain inventory, and that it was appointing a new chief executive officer. On this news, Aurora's stock fell approximately 11.6% in just one day. Since May 2020, Aurora's stock is down approximately $12.80 per share, or 74%.

A lawsuit alleging violations of federal securities laws has been filed against Aurora and certain of its officers and directors. Lawless v. Aurora Cannabis Inc., et al. , No. 20-cv-13819 (D.N.J.). The suit, which has a class period running from February 13, 2020 to September 4, 2020, alleges, among other things, that Aurora misled investors as to the value of prior acquisitions, that the Company had experienced degradation in certain assets, and that as a result, it was foreseeable that Aurora would record significant goodwill and asset impairment charges. According to the lawsuit, this news was so shocking because Aurora had previously lauded a "business transformation plan" that would purportedly "better align the business financially with the current realities of the cannabis market."

If you purchased or acquired shares of GOCO, NXTC, or ACB and have questions about your legal rights or possess information relevant to these matters, please contact Block & Leviton attorneys at (617) 398-5600, via email at cases@blockleviton.com , or via the links provided above.

Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country's financial markets. The firm represents many of the nation's largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm's lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: cases@blockleviton.com
SOURCE: Block & Leviton LLP
www.blockleviton.com

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Analytical testing will accelerate Numinus' Research and Development capabilities and generate revenue through third-party clients

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, has today announced novel, proprietary methods for psychedelic mushroom compound screening. The testing, which was developed and validated in-house, will be available as part of its service offerings for third-party clients and used for evidence-based conversations with the regulators.

Keep reading... Show less

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cronos Group Inc. - CRON1111

Pomerantz LLP is investigating claims on behalf of investors of Cronos Group Inc. ("Cronos" or the "Company") (NASDAQ: CRON). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Cronos and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Keep reading... Show less
cannabis plant layered with German flag graphic

Cannabis Weekly Round-Up: Germany Moves Ahead on Path to Adult Use

Three political parties have formed a coalition in Germany, leading to a new government, and it has promised cannabis reform in the European nation.

Meanwhile, a popular cannabis retailer confirmed consumers will now find its products available for delivery on the Uber Eats mobile application in Ontario.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading... Show less
HEMPSANA Announces Q3 2021 Financial Results

HEMPSANA Announces Q3 2021 Financial Results

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.

Hempsana Holdings Ltd. (the " Company " or " Hempsana ") today announced third quarter ("Q3") financial results for the three- and nine-month period ended September 30, 2021.

Keep reading... Show less
Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

 Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange ("TSX") to graduate its listing from the TSX Venture Exchange (the "TSXV") to the TSX.

"This is an important milestone for Numinus, as we take key steps to heighten our corporate profile and reach a broader range of investors," said Payton Nyquvest , Founder and CEO of Numinus. "Today's announcement is reflective of many exciting developments occurring at Numinus. We're actively growing our clinic network across North America , expanding our lab capabilities, and strategically investing in clinical research to drive long-term value creation for our investors."

Keep reading... Show less
MediPharm Labs Completes Medical Cannabis Export to Barbados

MediPharm Labs Completes Medical Cannabis Export to Barbados

  • Patient based delivery of medical cannabis executed with approval from both Barbados and Canadian Health Authorities.
  • This marks the fourth new country entered by MediPharm Labs in 2021, following initial shipments to Germany, Brazil and Peru.

MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a medical cannabis export to Barbados in conjunction with strategic partner Avicanna (TSX: AVCN).

"Our GMP platform make us the go-to partner for companies looking to access global medical cannabis programs," said Bryan Howcroft, CEO, MediPharm Labs. "As countries around the world continue to adopt medical cannabis programs, MediPharm Labs is best positioned to serve these markets as the only North American producer with a Drug Establishment License (GMP) for the extraction of natural cannabinoids."

Keep reading... Show less

Top News

Related News